Transforming the biologics product lifecycle with inhalation innovation
Authors: Nicolas Buchmann and Frank Verhoeven
Publication: International Pharmaceutical Industry, Volume 16(1), 2024
Abstract: Biologics are reshaping modern healthcare, yet their full potential is often constrained by traditional administration routes. Recent advances in nasal inhalation, particularly soft mist nasal spray technologies, are redefining what is possible for sensitive biopharmaceutical formulations.
The rapid growth of both inhalation technologies and the global biologics market is creating new opportunities for patient-friendly, non-invasive drug delivery. Nasal inhalation and especially soft mist nasal spray technology, is emerging as a strong alternative to traditional parenteral routes, offering fast systemic uptake, improved patient experience, and expanded access beyond clinical settings.
However, biologics bring unique development challenges, including formulation sensitivity and the need for precise, consistent nasal deposition. Resyca’s next-generation soft mist nasal spray platforms address these barriers through biologic-compatible nozzle designs, controlled plume characteristics, and device architectures that minimise formulation stress while enhancing delivery efficiency.
As patent expiries accelerate competition in the biologics sector, nasal reformulation becomes a strategic path to lifecycle extension. Soft mist nasal sprays enable developers to differentiate existing products, streamline regulatory pathways, and unlock new therapeutic potential, positioning nasal delivery as a pivotal innovation for the next era of biopharmaceuticals.
